(B) Toxicities observed during maintenance immunotherapy in metastatic UM
| (B) | G1 (%) | G2 (%) | G3 (%) | Unknown (%) | Total (%) |
| Diarrhea/colitis | 0 (0.0) | 1 (3.8) | 0 (0.0) | 1 (3.8) | 2 (7.7) |
| Fatigue | 2 (7.7) | 0 (0.0) | 0 (0.0) | 1 (3.8) | 3 (11.5) |
| Hypoadrenalism | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (3.8) | 1 (3.8) |
| Hypothyroid | 1 (3.8) | 0 (0.0) | 0 (0.0) | 1 (3.8) | 2 (7.7) |
| Pneumonitis | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (3.8) | 1 (3.8) |
| Rash | 2 (7.7) | 0 (0.0) | 0 (0.0) | 2 (7.7) | 4 (15.4) |
| Transaminitis | 0 (0.0) | 1 (3.8) | 1 (3.8) | 1 (3.8) | 3 (11.5) |
Twenty-eight patients also experienced toxicities other than those listed above. Three patients had uveitis, one had DKA, two had AKI, one had myositis.
Seven patients also experienced toxicities other than those listed above.
AKI, acute kidney injury; DKA, diabetic ketoacidosis; UM, uveal melanoma.